We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Review of LUMEVOQ® dossier to resume compassionate access program in France is ongoing; in parallel, work continues on the new RECOVER Phase III clinical trial and marketing application to the MHRA ...

Reducing the number of intravitreal injections to treat age-related macular degeneration (AMD) is a top priority in current ...

Retinal Biologics MarketThe Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow to USD 41.92 billion by 2028, expanding at a CAGR of 11.1% from 2022 to ...

CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716, a novel therapeutic candidate ...

The Ocular Therapeutix logo and DEXTENZA ® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™ ...

This is a developing news story. Please check back soon for updates. The FDA approved expanded prescribing information for ...

This study demonstrates the critical role of Afadin on the generation and maintenance of complex cellular layers in the mouse retina. The data are solid, which provides important insights into how ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...